AIM: To investigate the mechanism of flavonoid extract from Dracocephalum rupestre hance (DRHF) in the treatment of gouty arthritis through network pharmacology, molecular docking and animal experiment. METHODS: Literature retrieval was used to explore the main active chemical components and targets of DRHF. Gouty arthritis disease targets were obtained using Gene Cards and OMIM databases, and drug-disease intersecting targets were obtained using Wayne online tools. protein-protein interactions (PPI) and other related network diagrams were constructed using Cytoscape software. GO and KEGG enrichment analyses were performed on the shared intersecting targets using Metascape database. A rat model of gouty arthritis was established by Coderre method; the swelling degree of ankle joint, gait behaviour scores of rats were observed, and hematoxylin-eosin (HE) staining was performed. ELISA and real-time PCR were used to detect the key targets predicted by the network pharmacology, and the effects of DRHF on the molecular mechanism and key targets of gouty arthritis were observed. RESULTS: A total of 7 active compounds and 129 candidate targets for the treatment of GA were obtained, including IL-6, IL-1β, RELA, TNF, PPARG, etc. and the KEGG enrichment results suggested that DRHF may be involved in PI3K-Akt, TNF, IL-17 and other signal transduction pathways. Animal results: HE staining showed that the thickening of synovial tissue was not obvious in each administered group, and synovial cell proliferation and inflammatory cell infiltration were significantly improved; compared with the normal group, the serum levels of TNF, IL-6, and IL-1β in the model group were significantly higher (P<0.05), and the mRNA of PPARG, IL-6 , and RELA in the synovial tissues were significantly higher; compared with the model group, the levels of TNF, IL-6, and IL-1β were significantly lower (P<0.05) in the low group of DRHF (0.45 g/kg) and high group of DRHF (0.9 g/kg), TNF, IL-6, IL-1β levels were significantly reduced (P<0.05); PPARG, IL-6 , RELA mRNA in synovial tissue were significantly reduced. CONCLUSION: DRHF inhibits IL-17/PI-3K/TNF signaling pathway by down-regulating the expression of IL-6, PPARG and RELA mRNA, decreasing the levels of IL-6, IL-1β and TNF, and then treating gouty arthritis.